UNICA IRIS Institutional Research Information System

PERSANO, MARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.886
NA - Nord America 1.812
AS - Asia 1.423
SA - Sud America 177
Continente sconosciuto - Info sul continente non disponibili 129
AF - Africa 34
OC - Oceania 4
Totale 23.465
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.346
US - Stati Uniti d'America 1.738
SG - Singapore 556
CN - Cina 395
VN - Vietnam 165
SE - Svezia 141
BR - Brasile 130
DE - Germania 86
FR - Francia 72
HK - Hong Kong 62
IN - India 61
FI - Finlandia 56
GB - Regno Unito 51
CA - Canada 42
NL - Olanda 34
BD - Bangladesh 27
KR - Corea 22
AT - Austria 19
PL - Polonia 18
JP - Giappone 17
AR - Argentina 16
IQ - Iraq 15
MX - Messico 14
TR - Turchia 12
ES - Italia 11
PK - Pakistan 11
PH - Filippine 10
AE - Emirati Arabi Uniti 9
IE - Irlanda 9
MA - Marocco 9
VE - Venezuela 8
ZA - Sudafrica 8
EC - Ecuador 7
ID - Indonesia 7
RU - Federazione Russa 7
SA - Arabia Saudita 7
BE - Belgio 6
IL - Israele 6
IR - Iran 6
TH - Thailandia 6
UZ - Uzbekistan 6
CO - Colombia 5
AU - Australia 4
CH - Svizzera 4
GR - Grecia 4
KG - Kirghizistan 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
DZ - Algeria 3
JO - Giordania 3
PE - Perù 3
PY - Paraguay 3
AL - Albania 2
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
CL - Cile 2
CR - Costa Rica 2
DM - Dominica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
KE - Kenya 2
LT - Lituania 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SV - El Salvador 1
TN - Tunisia 1
UA - Ucraina 1
UG - Uganda 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 23.337
Salva come PNG Salva come JPEG
Città #
Cagliari 18.189
Uta 989
Singapore 353
Ashburn 233
San Jose 175
Dallas 129
Boardman 103
Nyköping 77
Beijing 76
Los Angeles 72
Council Bluffs 63
Hong Kong 58
Chandler 55
Fairfield 51
Ho Chi Minh City 50
Hanoi 45
Hefei 44
Helsinki 42
New York 41
The Dalles 37
Santa Clara 35
Chicago 33
Rome 30
Seattle 26
Houston 25
Seoul 22
Shanghai 22
Lauterbourg 21
Munich 21
Amsterdam 19
Pune 19
São Paulo 19
Boston 18
Woodbridge 18
Buffalo 17
Cambridge 17
Guangzhou 16
Milan 16
San Diego 16
Wilmington 16
Columbus 15
Nuremberg 14
Salt Lake City 14
Frankfurt am Main 13
Montreal 13
Orem 13
Redondo Beach 13
Warsaw 12
Lappeenranta 11
Shenzhen 11
Stockholm 11
Toronto 11
Chennai 9
Düsseldorf 9
London 9
Rio de Janeiro 9
Tianjin 9
Haiphong 8
Roubaix 8
Vienna 8
Brooklyn 7
Dubai 7
Dublin 7
Zhengzhou 7
Da Nang 6
Paris 6
Phoenix 6
Tashkent 6
Tokyo 6
Atlanta 5
Baghdad 5
Belo Horizonte 5
Florence 5
Manila 5
Menlo Park 5
Naples 5
Turin 5
Wuhan 5
Bexley 4
Bishkek 4
Brussels 4
Changsha 4
Charlotte 4
Dong Ket 4
Johannesburg 4
La Maddalena 4
Maebashi 4
Manchester 4
Mexico City 4
Nanjing 4
Newark 4
North Bergen 4
Pittsburgh 4
Poplar 4
Porto Alegre 4
Portsmouth 4
Queens 4
Quito 4
Romainville 4
San Francisco 4
Totale 21.719
Salva come PNG Salva come JPEG
Nome #
Molecular-biology-driven treatment for metastatic colorectal cancer 2.777
New therapeutic targets in pancreatic cancer 1.654
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.547
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.371
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.225
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.095
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 998
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 985
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 966
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 943
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 882
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 877
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 779
Uncovering key targets of success for immunotherapy in pancreatic cancer 729
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 682
BRCA-mutant pancreatic ductal adenocarcinoma 623
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 612
Immune Checkpoint Inhibitors in the Treatment of HCC 598
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 596
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 390
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 376
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 337
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 323
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 306
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 281
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 225
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 219
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 215
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 212
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 205
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 177
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 118
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 110
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study 12
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers 10
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 6
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 4
Totale 23.465
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.327 0 65 4 47 57 107 68 164 112 154 244 305
2022/20233.457 301 460 353 253 266 336 167 257 238 379 291 156
2023/20243.389 144 130 116 191 285 576 596 252 191 206 335 367
2024/20259.142 2.411 2.892 824 954 437 609 481 53 103 161 84 133
2025/20263.379 265 192 244 276 236 234 783 306 232 280 176 155
2026/2027138 63 75 0 0 0 0 0 0 0 0 0 0
Totale 23.465